Film review

Maria Bellantone

Nature, 2006, vol. 441, issue 7092, 418-418

Abstract: Cancer stem cell function Stem cells that initiate and maintain cancers are so like normal stem cells that it's hard to design drugs to target them specifically. This is a serious problem as, for example, damaging blood stem cells in leukaemia therapy can cause haematopoietic failure and death. Now a study of the tumour suppressor PTEN, often inactivated in leukaemia and other cancers, pinpoints a major difference between self-renewal in normal and cancer stem cells. PTEN normally inhibits the phosphatidylinositol-3-OH kinase signalling pathway, limiting cell proliferation and survival. In the absence of PTEN, leukaemic stem cells proliferate, but normal stem cells are depleted. This suggests that PTEN-mimicking drugs may act against leukaemia yet preserve blood stem cells. Indeed, in Pten-deficient mice rapamycin kills leukaemic stem cells but rescues normal stem cell function. A separate study confirms PTEN's role in blood stem cell regulation.

Date: 2006
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/441418a Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:441:y:2006:i:7092:d:10.1038_441418a

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/441418a

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().